199 related articles for article (PubMed ID: 25153728)
1. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
[TBL] [Abstract][Full Text] [Related]
2. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.
Kim BR; Seo SH; Park MS; Lee SH; Kwon Y; Rho SB
Oncotarget; 2015 Oct; 6(31):31830-43. PubMed ID: 26378810
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.
Dodd KM; Yang J; Shen MH; Sampson JR; Tee AR
Oncogene; 2015 Apr; 34(17):2239-50. PubMed ID: 24931163
[TBL] [Abstract][Full Text] [Related]
4. GABARBP down-regulates HIF-1α expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways.
Park SH; Kim BR; Lee JH; Park ST; Lee SH; Dong SM; Rho SB
Cell Signal; 2014 Jul; 26(7):1506-13. PubMed ID: 24686084
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
Li G; Shan C; Liu L; Zhou T; Zhou J; Hu X; Chen Y; Cui H; Gao N
PLoS One; 2015; 10(2):e0117440. PubMed ID: 25659153
[TBL] [Abstract][Full Text] [Related]
6. sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
Byun HJ; Kim BR; Yoo R; Park SY; Rho SB
Apoptosis; 2012 Oct; 17(10):1095-103. PubMed ID: 22903553
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
8. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
9. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the proliferation of hypoxia-Induced retinal pigment epithelial cell by rapamycin through the /mTOR/HIF-1α/VEGF/ signaling.
Liu NN; Zhao N; Cai N
IUBMB Life; 2015 Jun; 67(6):446-52. PubMed ID: 25988388
[TBL] [Abstract][Full Text] [Related]
11. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway.
Zhang J; Cao J; Weng Q; Wu R; Yan Y; Jing H; Zhu H; He Q; Yang B
PLoS One; 2010 Nov; 5(11):e13910. PubMed ID: 21085474
[TBL] [Abstract][Full Text] [Related]
12. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
13. Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells.
Weng Q; Zhang J; Cao J; Xia Q; Wang D; Hu Y; Sheng R; Wu H; Zhu D; Zhu H; He Q; Yang B
Invest New Drugs; 2011 Dec; 29(6):1177-87. PubMed ID: 20524035
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
Jiang H; Feng Y
Int J Gynecol Cancer; 2006; 16 Suppl 1():405-12. PubMed ID: 16515634
[TBL] [Abstract][Full Text] [Related]
15. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
16. Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1α via mTOR/4E-BP1 signaling pathways.
Ma J; Li J; Wang KS; Mi C; Piao LX; Xu GH; Li X; Lee JJ; Jin X
Int Immunopharmacol; 2016 Oct; 39():1-9. PubMed ID: 27394002
[TBL] [Abstract][Full Text] [Related]
17. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.
Mi C; Ma J; Wang KS; Zuo HX; Wang Z; Li MY; Piao LX; Xu GH; Li X; Quan ZS; Jin X
J Ethnopharmacol; 2017 May; 203():27-38. PubMed ID: 28341244
[TBL] [Abstract][Full Text] [Related]
18. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
19. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
Su S; Dou H; Wang Z; Zhang Q
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):224-233. PubMed ID: 32905663
[TBL] [Abstract][Full Text] [Related]
20. Theasaponin E
Li B; Tong T; Ren N; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
